NEW AGENTS ON THE HORIZON: IMPLICATIONS FOR PHASE I, II & III TRIALS DNA Repair and PARP inhibitors Carol Aghajanian, Nicoletta Colombo & Amit Oza Acknowledgements:
WHAT WILL THE KEY ISSUES IN END- POINT ASSESSMENT BE, IN FUTURE OVARIAN CANCER TRIALS INVOLVING NOVEL TARGETED AGENTS? first line treatment maintenance/consolidation.
Annexin V
first line treatment maintenance/consolidation treatment of recurrent disease
